risks of glp 1 drugs Your guide to GLP-1 side effects risks of glp-1 drugs The

Description

12,13 Modifications to prolong the half-life of GLP-1 RAs include sequence substitutions conferring resistance to DPP-4, along with acylation (liraglutide and semaglutide), covalent bonding to modified Ig fragment crystallisable domain (dulaglutide), or covalent bonding to albumin

2025;8(3):e250081

Adverse Effects and Long-Term Safety Concerns While GLP-1 receptor agonists have shown significant benefits, their widespread use is limited by potential side effects such as gastrointestinal distress, pancreatitis risk, and concerns over long-term metabolic effects

To view or add a comment, sign in Drug of the day Rilzabrutinib is a drug that acts as a Brutons tyrosine kinase (BTK) inhibitor

Over-the-counter alternatives like orlistat delivered only 23% incremental weight loss in 2024 meta-analyses, reinforcing prescriber reliance on higher-efficacy options